- Previous Close
0.1500 - Open
0.2649 - Bid --
- Ask --
- Day's Range
0.2649 - 0.2649 - 52 Week Range
0.2649 - 0.2649 - Volume
278 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9350 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
www.neurosense-tx.comRecent News: NRSNW
View More
Compare To: NRSNW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRSNW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-150.79%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.8M
Diluted EPS (ttm)
-0.9350
Balance Sheet and Cash Flow
Total Cash (mrq)
1.21M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.63M
Research Analysis: NRSNW
View MoreCompany Insights: NRSNW
NRSNW does not have Company Insights